// App-Quantinova.ai

107 : An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

Researchers

Presenter

  • David Planchard

Principal Investigators

  • Benjamin Besse

  • Harry J.M. Groen

  • Pierre Jean Souquet

  • Elisabeth A. Quoix

  • Christina S. Baik

  • Fabrice Barlesi

  • Tae Min Kim

  • Julien Mazieres

  • Silvia Novello

  • James R. Rigas

  • Allison Upalawanna

  • Anthony Michael D'amelio

  • Pingkuan Zhang

  • Bijoyesh Mookerjee

  • Bruce E. Johnson

Medical Centers

  • Gustave Roussy Cancer Campus, Villejuif, France

  • University of Groningen and University Medical Center Groningen, Groningen, Netherlands

  • Hopital Lyon Sud, Pierre-Benite, France

  • University Hospital of Strasbourg, Strasbourg, France

  • University of Washington, Seattle, WA

  • Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France

  • Rangueil-Larrey Hospital, Paul Sabatier University, Toulouse, France

  • Department of Oncology, University of Turin, Orbassano (TO), Italy

  • Geisel School of Medcn At Dartmouth, Lebanon, NH

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • Italy

  • Netherlands

  • Switzerland

  • United States

  • France

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT01336634

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved